Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

Any hopes of differentiation could come down to side effects.

The company is stepping back in second-line breast cancer.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.

But this adds another complexity, and has camizestrant really scored a first-line win?

Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.

Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.

First-in-human study starts include radioligands from Akiram and Philogen.